FCM
LYEL icon

Fortis Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Fortis Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-605
Closed -$6.51K – 176
2025
Q1 		$6.51K Hold
605
– – ﹤0.01% 154
2024
Q4 		$7.74K Hold
605
– – ﹤0.01% 134
2024
Q3 		$16.7K Hold
605
– – ﹤0.01% 130
2024
Q2 		$17.5K Hold
605
– – ﹤0.01% 128
2024
Q1 		$27K Buy
+605
New +$25.9K 0.01% 117

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fortis Capital Management's LYEL Position: Q2 2025 in Review

Fortis Capital Management sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 605 shares — an estimated $6.51K sold.

Fortis Capital Management first reported a position in LYEL in Q1 2024 and held it in 5 quarters. The position peaked at $27K in Q1 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Fortis Capital Management reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Fortis Capital Management sold 605 Lyell Immunopharma shares in Q2 2025, an estimated $6.51K.
  • Fortis Capital Management first reported a position in Lyell Immunopharma in Q1 2024 and held it in 5 quarters.
  • Fortis Capital Management's Lyell Immunopharma position peaked at $27K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Fortis Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.